ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SIGA SIGA Technologies Inc

6.00
0.06 (1.01%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
SIGA Technologies Inc NASDAQ:SIGA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.06 1.01% 6.00 5.98 6.00 6.11 5.88 5.94 159,035 22:00:00

SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results

31/10/2024 11:30am

GlobeNewswire Inc.


SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart


From Oct 2024 to Dec 2024

Click Here for more SIGA Technologies Charts.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.

Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.

A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1146096. The archived webcast will be available in the Investor Relations section of the Company's website.

About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe and the UK for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit http://www.siga.com.

Contacts:Suzanne Harnettsharnett@siga.comand 
InvestorsMedia
Jennifer Drew-Bear, Edison GroupJdrew-bear@edisongroup.comHolly Stevens, Berry & Companyhstevens@berrypr.com

1 Year SIGA Technologies Chart

1 Year SIGA Technologies Chart

1 Month SIGA Technologies Chart

1 Month SIGA Technologies Chart

Your Recent History

Delayed Upgrade Clock